tbuckley/cabot-search huggingface dataset:
Abstract LB-272: A novel isoform of Sox5 is expressed in TRAF3-deficient mouse B lymphomas
Authors: Shanique K.E. Edwards, Anand Desai, Carissa R. Moore, Yan Liu, Ronald P. Hart, Ping Xie
Journal: Cancer Research (2012)

Abstract TRAF3 is a novel tumor suppressor identified in human non-Hodgkin lymphoma and multiple myeloma. We recently reported that TRAF3 deletion causes vastly prolonged survival of mature B cells, which eventually leads to B lymphoma development in mice. The long latency of B lymphoma development observed in B-TRAF3−/− mice suggest that additional oncogenic pathways are required for B lymphomagenesis. To delineate such oncogenic pathways in TRAF3−/− B lymphomas, we performed microarray analyses and identified Sox5 as a gene recurrently up-regulated in B lymphomas spontaneously developed in different individual B-TRAF3−/− mice. We confirmed the striking up-regulation of Sox5 expression in TRAF3−/− B lymphomas at both the mRNA and protein levels by quantitative real time PCR and Western blot analyses, respectively. We further cloned the full-length cDNA of Sox5 from B lymphomas derived from 4 different individual B-TRAF3−/− mice. Surprisingly, we found that the sequence of Sox5 expressed in TRAF3−/− B lymphomas represents a novel isoform of Sox5, which has not been previously reported. This new isoform of Sox5 contains a 35 aa deletion in the N-terminal region in front of the leucine zipper domain. When transduced into human multiple myeloma cells, the cloned Sox5 cDNA was expressed into a protein of 80 kDa, a size identical to that detected in TRAF3−/− B lymphomas. Taken together, our findings identified a novel isoform of Sox5 as a candidate oncogene in B lymphoma. Our ongoing experiments will further elucidate the roles and mechanisms of Sox5 in TRAF3 deficiency-initiated B cell malignant transformation. This study is supported by a seed grant from the New Jersey Commission on Cancer Research (10-1066-CCR-EO, P. Xie), a Faculty Research Grant (P. Xie), and the Arthur Herrmann Endowed Cancer Research Fund (P. Xie); supported in part by a grant from NCI (R. Hart) and an Aresty Research Grant (A. Desai). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-272. doi:1538-7445.AM2012-LB-272
Mastoid Bone as a Single Site of Metastasis of Neuroendocrine Tumor
Authors: JOHN A. VENTO, VERONICA SOLIS, RICHARD P. SPENCER, MOZAFAREDDIN K. KARIMEDDINI
Journal: Clinical Nuclear Medicine (2003)

VENTO, JOHN A. M.D.; SOLIS, VERONICA M.D.; SPENCER, RICHARD P. M.D., PH.D.; KARIMEDDINI, MOZAFAREDDIN K. M.D. Author Information
The Invisible Patient
Authors: M Sirmon, R Kreisberg
Journal: New England Journal of Medicine (1996)

A 79-year-old woman who had a three-month history of near-syncopal episodes associated with transient confusion and slurred speech was admitted to the hospital. Her son, an emergency medical technician, noted a rapid irregular pulse during one episode. Paroxysmal atrial fibrillation with a rapid ventricular response was documented during Holter monitoring. Medication was not started.This is an older woman with recurrent spells that seem to be associated with a tachyrhythmia that was subsequently determined to be paroxysmal atrial fibrillation. Atrial fibrillation is common in this age group even in the absence of detectable cardiac or systemic disease. At . . .
NEED FOR PERMANENT PACEMAKER FOLLOWING IMPLANTATION OF THE REPOSITIONABLE LOTUS™ VALVE FOR THE TRANSCATHETER AORTIC VALVE REPLACEMENT IN 250 PATIENTS: RESULTS FROM THE REPRISE II TRIAL EXTENDED COHORT
Authors: Nicolas Dumonteil, Ian Meredith, Daniel Blackman, Didier Tchetche, David Hildick-Smith, Mark S. Spence, Darren Walters, Jan Harnek, Stephen Worthley, Gilles Rioufol, Thierry Lefevre, Thomas Modine, Nicolas Van Mieghem, Dominic Allocco, Keith Dawkins
Journal: Journal of the American College of Cardiology (2015)
Abstract A66: K12/SECTM1 promotes melanoma tumor progression via upregulation of integrin β3 expression
Authors: Tao Wang, Alfonso Lopez-Coral, Alexander Roesch, Catherine Huang, In-Chul Cha, Wei-Ting Hwang, Stefanie Meyer, Thomas Vogt, Meenhard Herlyn, Russel E. Kaufman
Journal: Cancer Research (2009)

Abstract Metastatic melanoma is a leading cause of mortality in skin cancers with few therapeutic options. However, molecular mechanisms underlying melanoma tumorigenesis and metastasis remain poorly understood. Here, for the first time, we have determined a specific role of K12/SECTM1(SECTM1) in melanoma pathogenesis. Microarray analysis of melanoma revealed that SECTM1 is higher expressed in melanoma cell lines compared to melanocytes. We confirmed that SECTM1 was upregulated in most melanoma cell lines both at the transcriptional and post-transcriptional level. In addition, SECTM1 is highly expressed in patient melanoma lesions both in primary and metastasis samples. Furthermore, overexpression of SECTM1 in melanoma cell line WM3899 dramatically increased cell invasion in vitro, and promoted tumor growth and metastasis in vivo. Consistently, reduction of SECTM1 expression in melanoma cell line WM9 inhibited tumor growth and metastasis in vivo. Mechanistically, SECTM1 upregulated expression of integrin β3 (ITGβ3), thus contributing to the progressive phenotype of SECTM1 in melanoma. Hence, this study identified SECTM1 as a novel melanoma metastasis gene. We anticipate that our findings will provide new avenues in the pathogenesis of melanoma metastasis and that targeting of SECTM1 could be a novel approach to inhibit melanoma progression. Citation Information: Cancer Res 2009;69(23 Suppl):A66.
AB0743 Prevalence of the Metabolic Syndrome According to Various Definitions in Patients with Psoriatic Arthritis
Authors: C. Papagoras, T.E. Markatseli, H.J. Milionis, E. Kaltsonoudis, P.V. Voulgari, A.A. Drosos
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> There is evidence that inflammatory joint disease is associated with increased cardiovascular risk. Systemic inflammation and reduced physical activity may be involved through changes in insulin sensitivity and obesity, thus allowing for the emergence of the metabolic syndrome. <h3>Objectives</h3> To study the prevalence and components of the metabolic syndrome in patients with psoriatic arthritis (PsA) in comparison with healthy controls. <h3>Methods</h3> Non-diabetic patients with PsA followed at a single center and age- and sex- matched healthy controls were included in the study. The metabolic syndrome was defined according to the National Cholesterol Education Program: Adult Treatment Panel III (NCEP:ATP III), the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), the International Diabetes Federation (IDF) and the Joint Interim Statement (JIS) criteria<sup>1</sup>. <h3>Results</h3> Seventy-one PsA patients and 51 healthy controls were included. Patients had significantly lower HDL levels than controls (p&lt;0.001). According to the NCEP:ATP III, AHA/NHLBI, IDF and the JIS criteria respectively, 22.5%, 39.4%, 43.7% and 49.3 of PsA patients had the metabolic syndrome compared to 11.8%, 15.7%, 21.6% and 23.5% of healthy controls (p=0.127 for the NCEP:ATP III, p=0.005 for the AHA/NHLBI, p=0.011 for the IDF and p=0.004 for the JIS criteria). Focusing on the individual metabolic syndrome criteria, PsA patients fulfilled more often the “low HDL” criterion compared to controls (p=0.008). <h3>Conclusions</h3> Although the proportion of PsA patients with the metabolic syndrome varies widely by the definition used, it seems that the syndrome is more prevalent in PsA than healthy subjects. Low HDL levels appear to be the main factor driving this difference. <h3>References</h3> Circulation. 2009;120:1640-5. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3169
SEVERITY OF MITRAL REGURGITATION AFTER MITRACLIP IN PATIENTS WITH VERSUS WITHOUT PULMONARY HYPERTENSION: RESULTS OF A MULTICENTER WORLDWIDE REGISTRY
Authors: Jose Francisco Condado Contreras, Neha Maheshwari Mantri, Gagan Singh, Benjamin Stripe, Gaurav Sharma, Thomas Smith, Dali Fan, Reginald Low, Jonathan Yap, Khung Yeo, Dan Arnett, James McCabe, Mark Reisman, Jason Rogers, Vasilis Babaliaros
Journal: Journal of the American College of Cardiology (2016)
SAT0055 Exploration of Risk Factors for Rheumatoid Arthritis Using Advance Recursive Partitioning Approach
Authors: N. Molano-Gonzalez, M. Arcos-Burgos, A. Rojas-Villarraga, J.-M. Anaya
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> A major challenge for rheumatoid arthritis (RA) research is the detection of subjects at risk. The tradeoff between complexity and interpretability is a key issue in the application of predictive models. Advance recursive partitioning (tree-based) approach (ARPA) is widely used in predictive analyses as it accounts for non-linear effects, offers fast solutions for hidden complex substructure and provides truly non-biased, statistically significant analyses of high dimensional, seemingly unrelated data. <h3>Objectives</h3> To evaluate a prediction model for RA using ARPA. <h3>Methods</h3> Classification and regression trees (CART), TreeNet and random forest models implemented in the Salford Predictive Modeler® (SPM7) were used in order to evaluate the predictive power of 21 genetic markers including HLA and non-HLA together with clinical data in 368 patients with RA (ACR87) and 353 matched controls. Different set of hyperparameters like RA risk priors, costs matrices, number of cross-validations, splitting rules, among others were evaluated in search for an optimal model. <h3>Results</h3> The TreeNet and random forest models showed good predictive performance, obtaining low misclassification error rates suitable for risk prediction (AUC=0.90 and 0.88, respectively) whereas the CART model showed lesser predictive power (AUC=0.71), but still acceptable. CART model allowed direct interpretation of genetic interactions. Interesting matches were observed including HLA-DRB1*04, HLA-DQB1, IL2/IL21 (rs6822844) and gender. <h3>Conclusions</h3> Our findings offer a predictive framework for RA based on interactions of genetic variants and epidemiological data. Improvements in clinical risk prediction will allow to identify novel targets for translation into personalized health care. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5226
The Effects of Treatment with Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone Deficiency
Authors: Franco Salomon, Ross C. Cuneo, Richard Hesp, Peter H. Sönksen
Journal: New England Journal of Medicine (1989)

In a double-blind, placebo-controlled trial, we studied the effects of six months of growth hormone replacement in 24 adults with growth hormone deficiency. Most of the patients had acquired growth hormone deficiency during adulthood as a consequence of treatment for pituitary tumors, and all were receiving appropriate thyroid, adrenal, and gonadal hormone replacement. The daily dose of recombinant human growth hormone (rhGH) was 0.07 U per kilogram of body weight, given subcutaneously at bedtime. The mean (±SE) plasma concentration of insulin-like growth factor I increased from 0.41±0.05 to 1.53±0.16 U per liter during rhGH treatment. Treatment with rhGH had no effect on body weight. The mean lean body mass, however, increased by 5.5±1.1 kg (P<0.0001), and the fat mass decreased by 5.7±0.9 kg (P<0.0001) in the group treated with growth hormone; neither changed significantly in the placebo group. The basal metabolic rate, measured at base line and after one and six months of rhGH administration, increased significantly; the respective values were 32.4±1.4, 37.2±2.2, and 34.4±1.6 kcal per kilogram of lean body mass per day (P<0.001 for both comparisons). Fasting plasma cholesterol levels were lower (P<0.05) in the rhGH-treated group than in the placebo group, whereas plasma triglyceride values were similar in the two groups throughout the study. We conclude that growth hormone has a role in the regulation of body composition in adults, probably through its anabolic and lipolytic actions. (N Engl J Med 1989; 321:1797–803.)
O3.03 * THE SPECTRUM OF LATE PAROXYSMAL NEUROLOGICAL SYNDROMES AFTER BRAIN IRRADIATION
Authors: G. Berzero, P. N.-o. Group, F. Ducray, B. Giometto, A. Silvani, A. Salmaggi, M. Eoli, G. Finocchiaro, A. Vidiri, A. Pace
Journal: Neuro-Oncology (2014)

INTRODUCTION: Late delayed multifocal paroxysmal neurological syndromes, known as stroke-like migraine attacks after radiation therapy (SMART), peri-ictal pseudoprogression (PIPG) and acute late-onset encephalopathy after radiotherapy (ALERT), have been recently reported after brain irradiation (RT). These syndromes share clinical and neuro-radiological features and might result from a common radiation-induced damage. Their diagnosis is challenging even for expert neurologists, as they have to be differentiated from a broad spectrum of complications, such as tumor progression, seizures, and toxic/metabolic encephalopathies. METHODS: We conducted a retrospective study in five institutions. Patients' inclusion criteria were 1) a remote history of brain irradiation; 2) the appearance of acute/subacute neurological signs and symptoms not related to tumor progression or epilepsy; 3) the presence of MRI abnormalities. Patients with stroke and transient “stroke-like” focal neurological signs in absence of ischemic/hemorrhagic lesions were included in the study. In all cases a thorough diagnostic workup was performed to exclude all other possible aetiologies. We identified 16 patients matching these criteria, and their clinical records were reviewed. RESULTS: Five patients presented a typical SMART pattern. Clinical presentation was characterized by hemianopia (3/5), confusion (2/5), headache (2/5), aphasia (2/5). Recovery was complete in 3 out of 5 patients after median interval of 8 days after symptom onset. Five patients presented ALERT syndrome. Clinical presentation was characterized by stupor/coma (5/5), headache (3/5), aphasia (3/5) and hemiparesis (3/5). All patients were treated with high dose steroids. Recovery was complete in 3 out of 5 patients after median interval of 9 days. Two patients presented an ischemic lesion within the radiation field, and were put on antiplatelet drugs. Four patients presented transient “stroke-like” events. Clinical presentation was characterized by aphasia (2/4), motor/sensory hemisyndrome (3/4). Two patients received antiplatelet drugs. Recovery was complete within hours or days in 3 out of 4 patients. We did not observe cases of PIPG in this series. In none of the patients tumor relapse occurred within the follow-up period. Three patients died due to pulmonary conditions. CONCLUSIONS: Long-term survivors after brain irradiation may present late paroxysmal neurological syndromes, that can be confused with tumor progression. Clinical presentation may be dramatic and recovery incomplete, resulting in residual severe morbidity. The aim of this report is to strengthen the observation of late delayed paroxysmal neurological syndromes after brain irradiation and to raise the neuro-oncologists' attention to the importance of developing adequate algorithms for the diagnosis and treatment of these conditions.
PWE-136 Pre-operative ERCP, cholecystitis and male gender are the major predictors of difficult cholecystectomies/conversion to open surgery
Authors: P Asaad, K G Pursnani, R S Date
Journal: Gut (2012)

<h3>Introduction</h3> Conversion to open surgery used to be a marker of difficult cholecystectomy. With increasing experience conversion rate has reduceed significantly, but the difficulties remain the same. Both, conversion and difficult cholecystectomy have impact on operation time. The aim of this study is to identify the major predictive factors for “difficult” cholecystectomies, which are either continued laparoscopically or subsequently converted. <h3>Methods</h3> A retrospective review of all the consecutive laparoscopic cholecystectomies, performed by a single surgeon, in a district general hospital in the UK, from January to December 2011, was undertaken. Association of intra-operative difficulties or conversion to open surgery, with the following factors was studied—Age, gender, liver function tests, jaundice, cholecystitis, pre-operative ERCP, pancreatitis, and radiological findings. <h3>Results</h3> During the study period 180 patients underwent cholecystectomy, of which 10 were converted to open surgery (5.6%), while 30 (16.6%) others were deemed “difficult dissections” but the operations were still completed laparoscopically. Previous cholecystitis (n=45) seems to be the most important predictor of difficulty, with 71% of patients requiring conversion or being considered a “difficult dissection.” Another very useful predictor is previous ERCP (n=14), with 64.5% of these patients being either conversions or “difficult dissections.” The conversion rate and difficult laparoscopic dissection rate was 8% and 24% respectively for men (n=37) and 5% and 15% for women (n=143). Among the patients with previous pancreatitis, none required conversion and 29% had difficult dissections. The conversion and difficult dissection rates increased with age (7% and 4% for age&lt;40, 20% and 1% for age 40–60, and 20.5% and 9.5% for age&gt;60 respectively). <h3>Conclusion</h3> Bile duct stones managed with pre-operative ERCP, cholecystitis and male gender appear to be the major predictors of difficult cholecystectomies/conversion to open surgery. This ability to predict the difficulty of the procedure might help the surgeon prepare for any technical difficulties that may arise, organise the theatre list more efficiently, and offer the patient more accurate information and counselling prior to the procedure. <h3>Competing interests</h3> None declared.
SAT0451 Methotrexate Therapy may Prevent the Onset of Uveitis in Juvenile Idiopathic Arthritis
Authors: C. Papadopoulou, M. Kostik, M. Böhm, J. C. Nieto-Gonzalez, M. I. Gonzalez-Fernandez, M. C. Gallo, S. Calandra, A. Consolaro, A. Martini, A. Ravelli
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate whether early treatment with methotrexate (MTX) prevents the onset of uveitis in children with juvenile idiopathic arthritis (JIA). <h3>Methods</h3> The clinical charts of all consecutive patients seen between January 2002 and February 2011 who had a disease duration &lt; 1 year at first visit and had received a stable management for at least 2 years with or without MTX were reviewed. Patients who were given systemic medications other than MTX (except NSAIDs) were excluded. Patients with systemic arthritis, rheumatoid factor-positive arthritis, or enthesitis-related arthritis were also excluded. Other exclusion criteria were the development of uveitis before onset of arthritis or before first observation at study center, or the presence of active uveitis at first visit. MTX was administered at 15 mg/m<sup>2</sup>/week (maximum 25 mg/week) in all patients. In each patient, the 2-year follow-up period after first visit was examined to establish whether uveitis had or had not occurred. <h3>Results</h3> A total of 254 patients with a median disease duration at first visit of 0.3 years were included. As many as 91.6% of patients were ANA-positive. Eighty-six (33.9%) patients were treated with MTX, whereas 168 (66.1%) patients did not receive MTX. During the 2-year follow-up, 211 (83.1%) patients did not develop uveitis, whereas 43 (16.9%) patients had uveitis, which was diagnosed a median of 1.0 year after first visit. The frequency of uveitis was lower in patients who were given MTX than in patients who did not receive this medication (10.5% vs. 20.2%, respectively; p = 0.049). Survival analysis confirmed that patients treated with MTX had a lower probability of developing uveitis. <h3>Conclusions</h3> Early MTX therapy may prevent the onset of uveitis in children with JIA. The potential of MTX to reduce the incidence of ocular disease should be investigated in a randomized controlled trial. <h3>Disclosure of Interest</h3> None Declared
Abdominal Abscesses in Patients Having Surgery
Authors: S C Tsai, T H Chao, W Y Lin, S J Wang
Journal: Clinical Nuclear Medicine (2001)

Purpose Early detection of occult abscesses is important in patients with persistent fever after colorectal surgery. In this study, the authors evaluated the relative merits of computed tomographic (CT) and Ga-67 scans in the detection of intra-abdominal abscesses in patients who had just undergone colorectal surgery. Materials and Methods Thirty-four patients who underwent colorectal surgery were enrolled in the study. Ga-67 and CT scans were obtained in all patients. Ga-67 scintigraphy was performed 24 hours, and later as needed, after the injection of 111 MBq (3 mCi) Ga-67 citrate. Results Intra-abdominal abscesses were diagnosed in 16 of the 34 (47%) patients who had colorectal surgery. For CT scans, the overall accuracy, sensitivity, and specificity rates were 97.1%, 93.7%, and 100%, respectively. For the Ga-67 scans, the diagnostic accuracy, sensitivity, and specificity rates were 91.2%, 100%, and 95.2%, respectively. In addition, the whole-body Ga-67 scans successfully detected two cases of extra-abdominal infection, one case of pneumonia, and one case of cellulitis. Conclusions Computed tomographic and Ga-67 scans offer complementary information and play an important role in the investigation of sources of infection in patients after colorectal surgery.
Weak in the Knees
Authors: Walter D. Conwell, S. Andrew Josephson, Howard Li, Sanjay Saint, William J. Janssen
Journal: New England Journal of Medicine (2013)

A 61-year-old woman presented to her primary care physician with a 4-week history of progressive leg weakness, bilateral leg pain, and difficulty walking. The weakness was symmetric and did not fluctuate during the course of the day.
Two Sequential Tc-99m ECD SPECT Studies in a Case of Sporadic Creutzfeldt–Jakob Disease Confirmed at Autopsy
Authors: Barbara Paghera, Federico Caobelli, Lutfun Nisa, Erinda Puta, Barbara Borroni, Enrico Premi, Alessandro Padovani, Raffaele Giubbini
Journal: Clinical Nuclear Medicine (2011)

Background: Creutzfeldt–Jakob disease (CJD) is a subacute spongiform encephalopathy characterized by rapidly progressive dementia, hard to diagnose during life. Materials and Methods: We present a case of a patient with pathologically confirmed sporadic form of CJD in whom initial diagnostic tests were negative. Two sequential brain single-photon emission computed tomography with Tc-99m ethyl-cysteinate dimer were performed, the first one was performed few days after the admission into hospital and the second, 1 month later. Results: Both studies revealed a decrease in regional cerebral blood flow indicative of neuronal dysfunction, more pronounced in the second study. Conclusion: Current radionuclide scintigraphy can be an useful tool for the investigation of CJD.